Cargando…
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
Despite the recent advancement in treating melanoma, options are still limited for patients without BRAF mutations or in relapse from current treatments. BH3 mimetics against members of the BCL-2 family have gained excitement with the recent success in hematological malignancies. However, single dru...
Autores principales: | Mukherjee, Nabanita, Strosnider, Andrew, Vagher, Bay, Lambert, Karoline A., Slaven, Sarah, Robinson, William A., Amato, Carol M., Couts, Kasey L., Bemis, Judson G. T., Turner, Jacqueline A., Norris, David A., Shellman, Yiqun G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125485/ https://www.ncbi.nlm.nih.gov/pubmed/30185782 http://dx.doi.org/10.1038/s41419-018-0932-z |
Ejemplares similares
-
Enrichment of Melanoma Stem-Like Cells via Sphere Assays
por: Mukherjee, Nabanita, et al.
Publicado: (2021) -
A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
por: Dart, Chiara R., et al.
Publicado: (2021) -
DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
por: Milani, Mateus, et al.
Publicado: (2017) -
The Combination of BH3-Mimetic ABT-737 with the Alkylating Agent Temozolomide Induces Strong Synergistic Killing of Melanoma Cells Independent of p53
por: Reuland, Steven N., et al.
Publicado: (2011) -
DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis
por: Milani, Mateus, et al.
Publicado: (2019)